> Gilead Sciences ($GILD) has started the first of two Phase III clinical trials to evaluate a once-daily, single-tablet medication regimen containing tenofovir ...
Good day. The pandemic is prompting biotechnology companies to rethink their use of lab and office space. Demand for biotech work space hasn’t declined because of the pandemic, said Steve Purpura, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback